vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
STURM RUGER & CO INC is the larger business by last-quarter revenue ($151.1M vs $94.9M, roughly 1.6× DYNAVAX TECHNOLOGIES CORP). On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 3.6%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $12.3M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 5.1%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
DVAX vs RGR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $151.1M |
| Net Profit | $26.9M | — |
| Gross Margin | — | 17.8% |
| Operating Margin | 22.4% | 2.3% |
| Net Margin | 28.4% | — |
| Revenue YoY | 17.7% | 3.6% |
| Net Profit YoY | 53.0% | — |
| EPS (diluted) | $0.21 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $151.1M | ||
| Q3 25 | $94.9M | $126.8M | ||
| Q2 25 | $95.4M | $132.5M | ||
| Q1 25 | $68.2M | $135.7M | ||
| Q4 24 | $72.0M | $145.8M | ||
| Q3 24 | $80.6M | $122.3M | ||
| Q2 24 | $73.8M | $130.8M | ||
| Q1 24 | $50.8M | $136.8M |
| Q4 25 | — | — | ||
| Q3 25 | $26.9M | $1.6M | ||
| Q2 25 | $18.7M | $-17.2M | ||
| Q1 25 | $-96.1M | $7.8M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $17.6M | $4.7M | ||
| Q2 24 | $11.4M | $8.3M | ||
| Q1 24 | $-8.7M | $7.1M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | — | 2.3% | ||
| Q3 25 | 22.4% | -2.7% | ||
| Q2 25 | 15.1% | -15.6% | ||
| Q1 25 | -34.7% | 6.2% | ||
| Q4 24 | -2.3% | 7.8% | ||
| Q3 24 | 12.5% | 3.1% | ||
| Q2 24 | 7.0% | 6.9% | ||
| Q1 24 | -35.0% | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | 28.4% | 1.2% | ||
| Q2 25 | 19.6% | -13.0% | ||
| Q1 25 | -141.0% | 5.7% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 21.8% | 3.9% | ||
| Q2 24 | 15.4% | 6.3% | ||
| Q1 24 | -17.2% | 5.2% |
| Q4 25 | — | $0.22 | ||
| Q3 25 | $0.21 | $0.10 | ||
| Q2 25 | $0.14 | $-1.05 | ||
| Q1 25 | $-0.77 | $0.46 | ||
| Q4 24 | $0.07 | $0.62 | ||
| Q3 24 | $0.12 | $0.28 | ||
| Q2 24 | $0.08 | $0.47 | ||
| Q1 24 | $-0.07 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $283.8M |
| Total Assets | $946.5M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.5M | ||
| Q3 25 | $160.2M | $80.8M | ||
| Q2 25 | $99.1M | $101.4M | ||
| Q1 25 | $51.7M | $108.3M | ||
| Q4 24 | $95.9M | $105.5M | ||
| Q3 24 | $119.3M | $96.0M | ||
| Q2 24 | $112.5M | $105.6M | ||
| Q1 24 | $132.0M | $115.3M |
| Q4 25 | — | $283.8M | ||
| Q3 25 | $534.1M | $279.6M | ||
| Q2 25 | $494.2M | $289.3M | ||
| Q1 25 | $530.9M | $321.5M | ||
| Q4 24 | $596.8M | $319.6M | ||
| Q3 24 | $681.4M | $314.9M | ||
| Q2 24 | $642.8M | $321.5M | ||
| Q1 24 | $618.5M | $332.0M |
| Q4 25 | — | $342.0M | ||
| Q3 25 | $946.5M | $342.3M | ||
| Q2 25 | $918.4M | $349.5M | ||
| Q1 25 | $945.9M | $379.0M | ||
| Q4 24 | $986.3M | $384.0M | ||
| Q3 24 | $1.1B | $373.5M | ||
| Q2 24 | $1.0B | $376.7M | ||
| Q1 24 | $986.6M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $15.5M |
| Free Cash FlowOCF − Capex | $32.6M | $12.3M |
| FCF MarginFCF / Revenue | 34.4% | 8.2% |
| Capex IntensityCapex / Revenue | 1.3% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.5M | ||
| Q3 25 | $33.8M | $12.9M | ||
| Q2 25 | $23.4M | $14.7M | ||
| Q1 25 | $-19.6M | $11.1M | ||
| Q4 24 | $53.0M | $20.0M | ||
| Q3 24 | $19.5M | $9.4M | ||
| Q2 24 | $10.7M | $18.7M | ||
| Q1 24 | $-16.7M | $7.3M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $32.6M | $7.0M | ||
| Q2 25 | $22.0M | $9.1M | ||
| Q1 25 | $-23.6M | $10.0M | ||
| Q4 24 | $49.5M | $16.4M | ||
| Q3 24 | $18.1M | $2.6M | ||
| Q2 24 | $9.9M | $10.1M | ||
| Q1 24 | $-17.4M | $5.6M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | 34.4% | 5.5% | ||
| Q2 25 | 23.0% | 6.9% | ||
| Q1 25 | -34.6% | 7.4% | ||
| Q4 24 | 68.8% | 11.2% | ||
| Q3 24 | 22.5% | 2.1% | ||
| Q2 24 | 13.5% | 7.7% | ||
| Q1 24 | -34.3% | 4.1% |
| Q4 25 | — | 2.1% | ||
| Q3 25 | 1.3% | 4.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 5.8% | 0.8% | ||
| Q4 24 | 4.8% | 2.5% | ||
| Q3 24 | 1.7% | 5.5% | ||
| Q2 24 | 1.1% | 6.6% | ||
| Q1 24 | 1.5% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | 8.15× | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | 1.98× | ||
| Q2 24 | 0.94× | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
